Previous reports demonstrated a beneficial effect of targeting DDI2 using nelfinavir in cancer treatments (Chow et al., 2009) including in Multiple Myeloma (Besse et al., 2018; Driessen et al., 2016; Fassmannova et al., 2020; Gu et al., 2020; Hitz et al., 2019). This evidence concerns the gene DDI2 and plasma cell myeloma.